Adamis Pharmaceuticals Corp.
<p>Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is developing various products in the allergy and respiratory markets The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine <nobr>pre-filled</nobr> syringe (PFS), <nobr>APC-5000</nobr> dry powder inhaler (DPI), <nobr>APC-1000</nobr>, <nobr>APC-2000</nobr> and <nobr>APC-3000</nobr>, and biotechnology products, such as <nobr>TeloB-VAX</nobr> (vaccine), <nobr>APC-100</nobr>, <nobr>APC-200</nobr> and <nobr>APC-300</nobr>. The Company’s product candidates for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are <nobr>APC-5000</nobr> DPI and <nobr>APC-1000</nobr>. The Company’s other product candidates in its allergy and respiratory product pipeline include <nobr>APC-1000</nobr>, <nobr>APC-3000</nobr> and <nobr>APC-2000</nobr>. The Company’s drug candidates for the treatment of prostate cancer are <nobr>APC-100</nobr>, <nobr>APC-200</nobr> and <nobr>APC-300</nobr>. The Company also has a microbicide product candidate named Savvy (C31G). The Company’s product candidate for the treatment of anaphylaxis is Epinephrine PFS.</p>